Christoph C Carter

机构：Gilead Sciences (United States) · ORCID：0000-0001-7793-8011

发表论文 52 篇 · 总被引 3203 次 · h-index 20

代表论文

• Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (2024 · New England Journal of Medicine · 被引 473)
• Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (2024 · New England Journal of Medicine · 被引 261)
• Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials (2021 · Clinical Infectious Diseases · 被引 119)
• Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021 · The Lancet HIV · 被引 91)
• HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women (2024 · JAMA · 被引 79)
• Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study (2025 · The Lancet · 被引 52)